Finsgate
5-7 Cranwood Street
London EC1V 9EE
United Kingdom
June 2, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Dorrie Yale
Re: Renalytix plc
Registration Statement on Form F-3
Filed May 27, 2022
File No. 333-265280
Acceleration Request
Requested Date: June 6, 2022
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-265280) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on June 6, 2022, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Katie Kazem of Cooley LLP, counsel to the Registrant, at (703) 456-8043.
[Signature page follows]
| Very truly yours, | ||
| RENALYTIX PLC | ||
| By: | /s/ James McCullough | |
| James McCullough | ||
| Chief Executive Officer | ||
| cc: | O. James Sterling, Renalytix plc |
Marc Recht, Cooley LLP
Madison Jones, Cooley LLP
Katie Kazem, Cooley LLP